POLA1 and ovarian carcinoma: In another phase II trials conducted on patients with breast or ovarian cancer (NCT02203513), transcriptomic analysis revealed high levels of DNA replication‐related genes (i.e., POLA1, POLE, GINS3) associated with lack of clinical benefit, suggesting that POLA1 expression may predict Chk1 inhibitors resistance, and that its inhibition may improve the efficacy of prexasertib monotherapy.252